{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma+%28MM%29", "query": { "condition": "Multiple Myeloma (MM)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 185, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma+%28MM%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T08:57:04.394Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01081028", "title": "Connect® MM- The Multiple Myeloma Disease Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "First-line therapy", "type": "OTHER" }, { "name": "Second-line Multiple Myeloma treatments", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3011, "start_date": "2009-09-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 252, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01081028" }, { "nct_id": "NCT00317798", "title": "Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2006-04", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-08-30", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00317798" }, { "nct_id": "NCT06832865", "title": "ELISA in Relapsed/Refractory MM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Refractory Multiple Myeloma (RRMM)", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "elranatamab", "type": "DRUG" }, { "name": "Isatuximab SC", "type": "DRUG" }, { "name": "Isatuximab SC-OBDS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-14", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06832865" }, { "nct_id": "NCT04009109", "title": "Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma, Multiple" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 79, "start_date": "2020-10-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 7, "location_summary": "Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more", "locations": [ { "city": "Bangor", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009109" }, { "nct_id": "NCT04895410", "title": "Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lemzoparlimab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-01-17", "completion_date": "2022-06-24", "has_results": false, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 12, "location_summary": "Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895410" }, { "nct_id": "NCT06152575", "title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2024-02-08", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 97, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06152575" }, { "nct_id": "NCT04178902", "title": "A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma (MM)", "Cancer" ], "interventions": [ { "name": "ABBV-467", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-05-19", "completion_date": "2021-04-16", "has_results": false, "last_update_posted_date": "2021-07-26", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 5, "location_summary": "Tucson, Arizona • Duarte, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04178902" }, { "nct_id": "NCT04150965", "title": "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab, pomalidomide, dexamethasone", "type": "DRUG" }, { "name": "Anti-LAG-3", "type": "DRUG" }, { "name": "Anti-LAG-3 + Pomalidimide + Dexamethasone", "type": "DRUG" }, { "name": "Anti-TIGIT", "type": "DRUG" }, { "name": "Anti-TIGIT + Pomalidimide + Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-07-10", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150965" }, { "nct_id": "NCT07409246", "title": "A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "ABBV-438", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2026-02-27", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 5, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07409246" }, { "nct_id": "NCT02431208", "title": "A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2015-07-22", "completion_date": "2021-03-19", "has_results": false, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-06-07T08:57:04.394Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431208" } ] }